These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24393214)

  • 21. Desensitization for hypersensitivity reactions to medications.
    del Carmen Sancho M; Breslow R; Sloane D; Castells M
    Chem Immunol Allergy; 2012; 97():217-33. PubMed ID: 22613865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are antineoplastic drug acute hypersensitive reactions a submerged or an emergent problem? Experience of the Medical Day Hospital of the Fondazione IRCCS Istituto Nazionale Tumori.
    Ferrari LA; Fanetti G; Rossi FG; Brambilla MC; Re B; Buzzoni R
    Tumori; 2014; 100(1):9-14. PubMed ID: 24675484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity.
    Chung SJ; Kang SY; Kang RY; Kim YC; Lee KH; Kim TY; Han SW; Kang HR
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):777-785. PubMed ID: 30105458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new rapid desensitization protocol for chemotherapy agents.
    Gastaminza G; de la Borbolla JM; Goikoetxea MJ; Escudero R; Antón J; Espinós J; Lacasa C; Fernández-Benítez M; Sanz ML; Ferrer M
    J Investig Allergol Clin Immunol; 2011; 21(2):108-12. PubMed ID: 21462800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.
    Gammon D; Bhargava P; McCormick MJ
    Oncologist; 2004; 9(5):546-9. PubMed ID: 15477639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].
    Luiting J; de Monchy JG; Hiltermann TJ; Oude Elberink JN
    Ned Tijdschr Geneeskd; 2011; 155():A2980. PubMed ID: 21527052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
    Park SJ; Lee KY; Park WS; Min SY
    Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug desensitization in the management of hypersensitivity reactions to monoclonal antibodies and chemotherapy.
    Mezzano V; Giavina-Bianchi P; Picard M; Caiado J; Castells M
    BioDrugs; 2014 Apr; 28(2):133-44. PubMed ID: 23990250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children.
    Hong DI; Dioun AF
    J Allergy Clin Immunol Pract; 2014; 2(1):13-9; quiz 20. PubMed ID: 24565764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management and preparedness for infusion and hypersensitivity reactions.
    Lenz HJ
    Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation.
    Jones R; Ryan M; Friedlander M
    Gynecol Oncol; 2003 Apr; 89(1):112-5. PubMed ID: 12694663
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies: Safety and efficacy of desensitization.
    Villarreal-González RV; González-Díaz S; Vidal-Gutiérrez O; Cruz-de la Cruz C; Pérez-Ibave DC; Garza-Rodríguez ML
    J Oncol Pharm Pract; 2024 Jul; 30(5):811-822. PubMed ID: 37489025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience.
    Lafay-Cousin L; Sung L; Carret AS; Hukin J; Wilson B; Johnston DL; Zelcer S; Silva M; Odame I; Mpofu C; Strother D; Bouffet E
    Cancer; 2008 Feb; 112(4):892-9. PubMed ID: 18098210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review.
    Banerji A; Lax T; Guyer A; Hurwitz S; Camargo CA; Long AA
    J Allergy Clin Immunol Pract; 2014; 2(4):428-33. PubMed ID: 25017531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypersensitivity reactions associated with oxaliplatin.
    Saif MW
    Expert Opin Drug Saf; 2006 Sep; 5(5):687-94. PubMed ID: 16907658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.
    Caiado J; Venemalm L; Pereira-Santos MC; Costa L; Barbosa MP; Castells M
    J Allergy Clin Immunol Pract; 2013; 1(5):494-500. PubMed ID: 24565621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-sensitivity between taxanes in patients with breast cancer.
    Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
    Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies.
    Sloane D; Govindarajulu U; Harrow-Mortelliti J; Barry W; Hsu FI; Hong D; Laidlaw T; Palis R; Legere H; Bunyavanich S; Breslow R; Wesemann D; Barrett N; Brennan P; Chong HJ; Liu A; Fernandez J; Fanning L; Kyin T; Cahill K; Bankova L; Lynch A; Berlin S; Campos S; Fuchs C; Mayer R; Matulonis U; Castells M
    J Allergy Clin Immunol Pract; 2016; 4(3):497-504. PubMed ID: 26895621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.